PT-141: Research Overview

The short version

PT-141, known by its approved name bremelanotide, is a synthetic peptide that activates melanocortin receptors in the brain — chiefly MC4R — rather than acting on blood vessels the way older approaches to sexual function do. It is FDA-approved as an injectable for hypoactive sexual desire disorder (HSDD) in premenopausal women: a persistent, distressing loss of sexual desire not caused by another medical or relationship problem ^[5].

In the pivotal RECONNECT trials, women taking bremelanotide as needed reported statistically significant gains in desire and reductions in desire-related distress compared with placebo over 24 weeks ^[3]. The most common side effects were nausea, flushing, and headache ^[3][4]. Use outside the approved population — in men, in postmenopausal women, or for general sexual enhancement — is off-label and not studied to the same standard. This page reports what the label and the trials say; it recommends no dose for anyone.

What it is

PT-141 is a synthetic cyclic heptapeptide, a lactam-bridged analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) built from the same backbone as Melanotan II, with the C-terminal amide swapped for a carboxylic acid. Under its approved name, bremelanotide, it is manufactured and dispensed as a prescription injectable; under the name PT-141 it also circulates as an unregulated research-chemical product, a distinction that matters because only the pharmaceutical version has been through manufacturing and quality controls ^[5].

Structurally it belongs to the same melanocortin peptide family as Melanotan II, but where Melanotan II binds every melanocortin receptor, bremelanotide's regulatory and clinical evidence base is built specifically around its action at MC4R and MC3R ^[7].

How it works

Bremelanotide activates melanocortin 4 receptors (MC4R), and to a lesser extent MC3R, concentrated in the hypothalamus and limbic system — brain regions that govern motivation and reward rather than blood flow ^[3]. Activity in the medial preoptic area is thought to engage dopaminergic circuits tied to sexual desire and arousal, which is the mechanistic reason it is described as working centrally rather than peripherally.

An fMRI study in 31 premenopausal women with HSDD found that MC4R agonism increased subjective sexual desire for up to 24 hours and altered task-based brain activity — specifically amygdala-insula connectivity and cerebellar/motor-area activation — in response to erotic stimuli, direct neuroimaging evidence for a central mechanism ^[2]. That is distinct from PDE-5 inhibitors, which act on vascular smooth muscle rather than the brain.

What the research shows

The evidence base runs from animal mechanism studies through two Phase 3 trials and a year-long extension. In female rats, PT-141 selectively increased appetitive solicitational sexual behavior — the wanting/seeking phase — without changing motor activity, one of the earliest demonstrations that central melanocortin signaling shapes female sexual desire specifically ^[6]. In female Syrian hamsters, a 2025 study found bremelanotide did not change receptor expression in the brain's reward circuit and did not enhance conditioned place preference, a nuanced finding suggesting it does not act through the reward pathway the way some other agents do ^[1].

The regulatory case rests on RECONNECT: two identical Phase 3 randomized, double-blind, placebo-controlled trials in 1,267 premenopausal women with HSDD. As-needed subcutaneous bremelanotide (1.75 mg) produced a statistically significant improvement on the FSFI desire score (P<.001) and a significant reduction in desire-related distress (P<.001) over 24 weeks — both coprimary endpoints were met ^[3]. In the 52-week open-label extension, covering 684 women, no new safety signals emerged and the desire improvements held; the leading drug-related adverse events were nausea (40.4%), flushing (20.6%), and headache (12.0%) ^[4]. Earlier work in men with erectile dysfunction and in nonhuman primates had already shown that systemic administration produces dose-dependent erectile activity and activates hypothalamic neurons, establishing the central mechanism well before the HSDD approval ^[7].

Reported effects, cautions & safety

The reports below are anecdotal, not clinical evidence — drawn from peptide-user forums, patient-review sites, and clinic accounts rather than controlled trials, and no dose is attached to any of them.

The most consistently described benefit is a sense of desire that starts mentally rather than physically — people describe feeling "switched on" rather than simply more responsive. Reports of greater physical arousal and sensitivity follow closely, along with, less consistently, easier or more intense orgasm. In the off-label male research-use community, spontaneous erections are frequently described as arriving before conscious arousal, which people distinguish from how blood-flow-based approaches feel; this use has not been studied to the standard of the approved indication. Onset is commonly reported as delayed by thirty minutes to a few hours, with effects that can extend well beyond that window.

On the adverse side, nausea is by far the most reported complaint, typically starting within the first half hour, worst on a first exposure, and often present even in people who report no benefit at all — a real, recurring pattern people describe as getting every side effect and none of the desired one. Flushing, headache, injection-site irritation, and occasional tingling or drowsiness are frequently mentioned; skin, gum, or mole darkening is reported specifically with frequent use.

The clinical record adds several cautions beyond the anecdotal picture. Approval is limited to premenopausal women with HSDD; use in men or postmenopausal women is off-label and outside the studied population ^[5][3]. The label warns of a transient blood-pressure rise and advises against use in uncontrolled hypertension or known cardiovascular disease ^[5]. Nausea affects a large share of users over long-term dosing and is a leading reason for discontinuation ^[4][3]. Repeated frequent dosing has been linked to darkening of skin and mucous membranes, tied to the same receptor activity responsible for the desire effect ^[5]. Material sold outside the pharmaceutical supply chain as a "PT-141 research chemical" is not subject to identity or purity verification, and pregnancy or breastfeeding has not been studied for safety in this compound.

Where it fits in sexual & reproductive research

PT-141 is the one compound on this desk with a completed regulatory review behind it, which is why it anchors the theme rather than merely joining it. Melanotan II is its structural ancestor and shares the melanocortin mechanism, but binds every receptor in the family rather than the two central to bremelanotide's approved use, and its safety record is meaningfully different as a result. Kisspeptin sits upstream of both, acting on the hormone cascade that starts in the hypothalamus before melanocortin signaling engages the desire circuitry these two peptides target directly. See the comparison page for how the three line up side by side.